
DFTX Stock Forecast & Price Target
DFTX Analyst Ratings
Bulls say
Definium Therapeutics is well positioned for long-term success with their innovative next-generation therapeutics intended to address the underlying causes of psychiatric and neurological disorders, and their lead candidate, DT120 ODT, having received FDA Breakthrough Therapy Designation for GAD. The recent strong Phase 3 data for DT120 in MDD and the upcoming Phase 3 data for GAD, along with a diversified pipeline and potential for M&A activity in the space, make Definium a compelling investment opportunity with potential for further upside.
Bears say
Definium Therapeutics is facing risks in their late-stage pipeline of four Phase 3 trials for GAD and MDD, as well as potential operational challenges as they prepare for the launch of DT120 ODT. This, combined with a recent offering and additional share count, leads to a downward revision in our DCF-based price target from $60 to $58. While the company's probability of approval for their drugs is promising, their conservative launch timing and price assumptions may impact their potential peak sales of $3.8bn/3.4bn for MDD/GAD in 2037E.
This aggregate rating is based on analysts' research of Definium Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
DFTX Analyst Forecast & Price Prediction
Start investing in DFTX
Order type
Buy in
Order amount
Est. shares
0 shares